Nagaileben Co., Ltd. · TSE:7447

Nagaileben — H1 FY2016 Earnings Presentation

50 slides from Nagaileben's earnings presentation, April 2016

  1. Slide 1: Analyst Guide First-half FY2016

    ANALYST GUIDE First-half FY2016 April 2016 (Listed on the 1st Section of the Tokyo Stock Exchange; Code 7447) <Contact for information on this material: Mr. Ohno, Administration Headquarters (03-5289-8200)>

  2. Slide 2: I About NAGAILEBEN

    I About “NAGAILEBEN” 1915 ~ 2015

  3. Slide 3: 100th anniversary year; Past and Future

    100th anniversary year; Past and Future Started white robe business in 1915. Management style “Concentration” 1915 Started Business 2001 Listed on 2nd TSE Realization of high profitability 1969 Founded Manufacturing Division 2003 Established distribution with radical pursuit of efficiency center 197

  4. Slide 4: Outline

    Outline Establish competitive position in Strong growing market medical clothing market Doctor, Dentist, Nursing Staff*2 Care workers*3 Pharmacist*1 (2013) (2013) -Approximately 60% market share (2014) in domestic medical clothing 700,000 1,570,000 1,710,000 -Wide field, planning, manufacturing Peop

  5. Slide 5: Agenda

    Agenda I About “NAGAILEBEN” II Financial Review First-half FY2016 III Market Environment IV Forecast for FY2016 V Management Goals VI Rewarding shareholder-focused policies 4

  6. Slide 6: Overview First-half FY2016

    Overview First-half FY2016 Sales & Income 1 Net Sales recorded highest. Sales in 2Q exceeded the decrement in 1Q. Sales surpassed previous and forecast. Though there were temporary expenses and impact of change in foreign exchange rates, operating income surpassed forecast. The Change of Business En

  7. Slide 7: II Financial Review First-half FY2016

    II Financial Review First-half FY2016 6

  8. Slide 8: Financial Highlights <Statements of Income>

    Financial Highlights <Statements of Income> (millions of yen,%) First-half FY2016 % Change To Forecast % Composition % Composition % Change Net sales 6,938 +1.4 +1.3 100.0 - Gross profit 3,174 -0.4 +0.7 45.8 -0.8 Sales, general, and 1,464 +5.4 -0.9 21.2 +0.9 administrative expenses Operating income

  9. Slide 9: Financial Highlights <Balance Sheet>

    Financial Highlights <Balance Sheet> Major assets (¥ million %) Title Result Change Result Change % [Major changes from the previous fiscal year] Cash on hand at banks 15,399 -110 -0.7 Cash and cash equivalents down ¥110million Notes and accounts receivable 4,760 +50 +1.1 -Cash flows from operating

  10. Slide 10: Segments by item

    Segments by item Healthcare wear Patient wear Shoes Doctors' wear Utility wear Surgery wear 9

  11. Slide 11: Sales by Item

    Sales by Item Doctors'15.4% Utility 4.1% [Healthcare wear] Patient 10.4% -Sales in 1Q declined -16.1% year-on-year. As caught renewal contracts, which were postponed or planned in 2Q, got new contracts, sales in 2Q increased +12.3% year-on-year. Sales reached record. Surgery 9.6% Healthcare Shoes [D

  12. Slide 12: Sales by Region

    Sales by Region Central Japan [East Japan] 10.4% West Japan - Sales in 2Q grew smoothly, as catching renewal 38.8% contracts which were postponed in 1Q. Sales kept previous year. [Central Japan] -Market size was not large and there was the influence by the size of contracts. In this term, sales decl

  13. Slide 13: III Market Environment

    III Market Environment 12

  14. Slide 14: Market Environment Topics

    Market Environment Topics Medical treatment fees was revised.(effective Apr. 2016) -Revise rate -0.84%(Service: +0.49%, Drug price: -1.33%) -In addition to above, Revised Drug price -0.19% Exception -0.28% Recalculations for market expansion Escalating material prices, rising sewing costs -The price

  15. Slide 15: Market Environment

    Market Environment Changes and prospects for medical and care service systems Medical System Care Service System Medical Service Law, Health and Medical Medical treatment fees Care Service Law, Nursing Care Insurance, etc. Nursing care fees Service Law for the Aged, Medical Insurance, etc Proposed d

  16. Slide 16: Market Environment

    Market Environment Revisions to medical treatment and care Service fees (%) 5 Service: +0.49% 4 Drug price: -1.33% +2.8 +3.0 3 +2.6 Consumption tax increase 2 +1.0 +1.2 1 +0.8 +0.6 +0.4 +0.2 +0.2 +0.0 +0.1 0 -1 ▲0.3 ▲0.1 ▲0.8 ▲0.8 -2 ▲1.3 Consumption tax increase +1.63% Service -1.26% ▲2.3 ▲2.4 ▲2.3

  17. Slide 17: Market Environment: Supply and Demand of Nursing Staff

    Market Environment Supply and Demand of Nursing Staff (Source: the Ministry of Health, Labor and Welfare (December 2010)) (10,000 persons) Change to actual number as 175 Demand from the 7th Outlook. Forecast Actual Decreased number of nursing staff on both supply 150 and demand sides for technical r

  18. Slide 18: Market Environment: Supply and need for care workers

    Market Environment (10,000 persons) 300 Supply and estimated future need for care workers Forecast 253 250 Actual 200 150 253 100 163 171 151 128 136 143 120 109 114 50 96 85 64 72 55 0 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '25 Since the number of track records are subject to the i

  19. Slide 19: Market Environment: Supply and estimated future need

    Market Environment Supply and estimated future need (10,000 persons) 300 Nursing Staff care workers 253 250 forecast(maximum) forecast(minimum) 206 200 Actual 150 253 100 196 171 157 50 0 2013 2025 2013 2025 Actual record: Japanese Nursing Associations’ statistical data Ministry of Health, Labor and

  20. Slide 20: IV Forecast for FY2016

    IV Forecast for FY2016 19

  21. Slide 21: Management Tasks and Status

    Management Tasks and Status •Capture clusters of needs Marketing strategy in the healthcare wear market to boost sales •Increase peripheral business in products for patients and surgery •Develop new markets •Strengthen ties with material makers and trade firms Production strategy to •Develop new pro

  22. Slide 22: Forecast Statements of Income

    Forecast Statements of Income (millions of yen,%) FY2016E % Change (FY2015) Composition % Change Net sales 16,500 +2.2 - Gross profit 7,590 +0.8 -0.6 Sales, general, and administrative expenses 2,776 +2.1 0.0 Operating income 4,813 +0.0 -0.6 Recurring income 4,869 -4.3 -2.0 Net income 3,237 +0.3 -0.

  23. Slide 23: Forecast of Sales by Item

    Forecast of Sales by Item Sales by Item (¥ million) Year-on-year change FY2015 FY2016E 18,000 Sales -0.4% +2.2% 16,000 Shoes/Others 14,000 Healthcare wear -0.1% +2.2% Surgery wear 12,000 Doctors' wear -2.6% +2.5% 10,000 Patient wear Utility wear -9.8% -7.5% 8,000 Utility wear Patient wear +7.2% +4.7

  24. Slide 24: Forecast of Sales by Region

    Forecast of Sales by Region Sales by Region (¥ million) Year-on-year change FY2015 FY2016E 18,000 Total sales -0.4% +2.2% 16,000 14,000 Overseas East Japan -1.2% +1.7% 12,000 Central Japan +1.7% +1.4% West Japan 10,000 West Japan +0.0% +2.7% 8,000 Central Japan Overseas +5.4% +13.6% 6,000 4,000 East

  25. Slide 25: Product Strategy

    Product Strategy Sales by Product (¥ million) Year-on-year change FY2015 FY2016E 18,000 Sales -0.4% +2.2% 16,000 DC brand products -9.9% -11.4% DC brand 14,000 products High Functional products +3.8% +6.9% 12,000 High Functional Standard Functional -3.2% -0.8% 10,000 products products 8,000 Standard

  26. Slide 26: Production Strategy

    Production Strategy Production(Non-Consolidated) (¥ million) (%) 10,000 50 Composition FY2015 FY2016E Purchased products Domestic production 53.0 51.5 7,500 45 Overseas production 45.6 47.1 Overseas production Purchased products 1.5 1.4 5,000 40 Domestic production 2,500 35 Ratio of overseas product

  27. Slide 27: V Management Goals

    V Management Goals 26

  28. Slide 28: Business Direction

    Business Direction Sales Strategy -Increase peripheral business in products for patients and surgery. -Gain share In West Japan. -Develop and sale of high functional products. Profit Strategy -Driving the strategy of higher quality and value-added products. -The shift to overseas production. -The mi

  29. Slide 29: Sales by Products

    Sales Strategy FY2012 FY2015 FY2018E (3 terms ago) (Previous term) (3 terms later) net sales ¥15,175 million ¥16,150 million ¥17,500 million Healthcare Doctors' 58% 57% 16% 58% 16% 16% Sales by Item Utility 2% 6% 4% 9% Patient 8% Patient 11% 9% Surgery 10% Surgery 3% Others 3% 2% 12% Central Japan 1

  30. Slide 30: Net Sales and Gross Profit to Sales Ratio

    Net Sales and Gross Profit to Sales Ratio (¥ million) (%) 17,500 Net sales (left) 15,000 55 Gross profit to sales (right) 12,500 10,000 45 7,500 5,000 35 2,500 0 25 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 14 14 15 16E17E18E (FY) Note: Consol

  31. Slide 31: VI Rewarding shareholder-focused policies

    ⅤI Rewarding shareholder-focused policies 30

  32. Slide 32: Profit Reimbursement to Shareholders

    Profit Reimbursement to Shareholders Shareholder-focused policies - Improvement of transparency by proactive disclosure - Interactive communication with investors - Profit reimbursement by high dividends Dividend policy - Basic policy is to continue stable dividend payment with payout ratio of 50% -

  33. Slide 33: The History of Stock Value

    The History of Stock Value BPS EPS DPS (Yen) (円) (yen) (yen) (yen) 1,100 100 FY2001 532.5 50.8 12.5 FY2002 568.3 48.0 12.5 1,000 FY2003 604.0 52.4 15.0 FY2004 663.0 60.5 30.0 900 75 FY2005 700.0 56.7 30.0 ※1 FY2006 732.4 61.0 30.0 FY2007 764.3 61.9 30.0 800 FY2008 783.9 57.1 30.0 FY2009 791.0 42.9 3

  34. Slide 34: Actual Dividends Paid

    Actual Dividends Paid Total dividend Share buyback Payout ratio Total return ratio (Million yen) (Million yen) (non-c, %) (non-c, %) FY2001 475 0 27.6 27.6 FY2002 475 0 29.3 29.3 FY2003 530 1,697 29.7 124.6 FY2004 744 0 36.5 36.5 FY2005 1,117 0 56.9 56.9 FY2006 1,117 0 53.4 53.4 FY2007 1,117 0 53.1

  35. Slide 35: Management Philosophy

    Management Philosophy We will provide medical products and services of the highest quality, as the leading company to link "medical services" and "clothing." - Consistently challenging spirit to lead the industry - Achievement of contribution to society - "Respect for Harmony among People" people ar

  36. Slide 36: Notes on this material

    Notes on this material This material includes forecasts for the future. These forecasts are based on the judgment of the Company's management concerning currently available information. These future projections include assumptions or views based on assumptions, and therefore may be different from th

  37. Slide 37: Data File

    Data File First-half FY2016 (Listed on the 1st Section of the Tokyo Stock Exchange;Code 7447) <Contact for information on this material: Mr. Ohno, Administration Headquarters (03-5289-8200)>

  38. Slide 38: Index

    Index 1 … Sales by Item 2 … Sales by Product 3 … Sales by Region 4 … Rationalization of the Production System and Our Purchasing Strategy (Non-Consolidated) 5 … Statements of Income (Consolidated) 6 … Statements of Income (Non-Consolidated) 7 … Indices (Consolidated) 8 … Indices (Non-Consolidated) 9

  39. Slide 39: 1. Sales by Item

    1. Sales by Item (¥ million) First-half First-half FY 12/8 13/8 14/8 15/8 16/8E 15/8 16/8 Sales 15,175 15,625 16,214 16,150 16,500 6,840 6,938 (¥ million) Healthcare wear 8,769 9,039 9,440 9,429 9,640 4,011 4,021 18,000 Doctors' wear 2,483 2,566 2,674 2,604 2,670 1,046 1,067 Utility wear 864 796 743

  40. Slide 40: 2. Sales by Product

    2. Sales by Product (¥ million) First-half First-half (¥ million) FY 12/8 13/8 14/8 15/8 16/8E 15/8 16/8 18,000 Sales 15,175 15,625 16,214 16,150 16,500 6,840 6,938 DC brand products 1,024 933 938 846 750 366 305 16,000 High Functional products 6,547 7,212 7,795 8,090 8,650 3,457 3,716 Standard Func

  41. Slide 41: 3. Sales by Region

    3. Sales by Region (¥ million) First-half First-half FY 12/8 13/8 14/8 15/8 16/8E 15/8 16/8 (¥ million) Sales 15,175 15,625 16,214 16,150 16,500 6,840 6,938 18,000 East Japan 8,106 8,390 8,461 8,357 8,500 3,430 3,406 Central Japan 1,564 1,591 1,745 1,774 1,800 787 717 16,000 West Japan 5,386 5,508 5

  42. Slide 42: 4. Rationalization of the Production System and Purchasing Strategy

    4. Rationalization of the Production System and Our Purchasing Strategy(Non-Consolidated) (¥ million) First-half First-half (¥ million) (%) FY 12/8 13/8 14/8 15/8 16/8E 10,000 50 15/8 16/8 Domestic production 5,056 4,951 5,061 4,901 4,813 2,495 2,430 Overseas production 3,441 3,550 4,017 4,215 4,401

  43. Slide 43: 5. Statements of Income (Consolidated)

    5. Statements of Income (Consolidated) (¥ million) First-half First-half FY 12/8 13/8 14/8 15/8 16/8E 15/8 16/8 Net Sales 15,175 15,625 16,214 16,150 16,500 6,840 6,938 Gross profit 7,103 7,346 7,585 7,532 7,590 3,187 3,174 Sales, general, and administrative expenses 2,461 2,473 2,662 2,719 2,776 1,

  44. Slide 44: 6. Statements of Income (Non-Consolidated)

    6. Statements of Income (Non-Consolidated) (¥ million) First-half First-half FY 12/8 13/8 14/8 15/8 16/8E 15/8 16/8 Net Sales 15,166 15,616 16,199 16,141 16,500 6,831 6,937 Gross profit 6,794 7,031 7,270 7,218 7,270 3,053 3,034 Sales, general, and administrative expenses 2,493 2,482 2,662 2,718 2,77

  45. Slide 45: 7. Indices (Consolidated)

    7. Indices (Consolidated) First-half First-half (Unit) 11/8 12/8 13/8 14/8 15/8 15/8 16/8 Profitability ROE (%) 8.5 7.8 9.7 9.5 9.3 - - ROA (%) 13.0 14.3 15.0 13.5 13.0 - - Return on sales Net income (%) 17.1 15.6 20.0 19.9 20.0 - - ROE resolution Total Assets Turnover (Times) 0.4 0.4 0.4 0.4 0.4 -

  46. Slide 46: 8. Indices (Non-Consolidated)

    8. Indices (Non-Consolidated) First-half First-half (Unit) 11/8 12/8 13/8 14/8 15/8 15/8 16/8 Profitability ROE (%) 8.6 7.8 10.3 10.1 9.8 - - ROA (%) 13.1 14.1 15.7 14.2 13.7 - - Return on sales Net income (%) 15.9 14.4 19.3 19.4 19.4 - - ROE resolution Total AssetsTurnover (Times) 0.5 0.5 0.5 0.5 0

  47. Slide 47: 9. Statements of Income (Consolidated)

    9. Statements of Income (Consolidated) (¥ million,%) (¥ million,%) FY 14/8 14/8 Change(the previous year) First-half 15/8 First-half 16/8 Change(the previous year) Result Composition Result Composition Result Change % Result Composition Result Composition Result Change % Net Sales 16,214 100.0 16,15

  48. Slide 48: 10. Statements of Income (Non-Consolidated)

    10. Statements of Income (Non-Consolidated) (¥ million,%) (¥ million,%) FY 14/8 15/8 Change(the previous year) First-half 15/8 First-half 16/8 Change(the previous year) Result Composition Result Composition Result Change % Result Composition Result Composition Result Change % Net Sales 16,199 100.0

  49. Slide 49: 11. Balance Sheet (Consolidated)

    11. Balance Sheet (Consolidated) (¥ million,%) (¥ million,%) FY 14/8 15/8 Change(the previous year) First-half 15/8 First-half 16/8 Change(the previous year) Result Composition Result Composition Result Change % Result Composition Result Composition Result Change % Current assets 29,589 75.6 29,711

  50. Slide 50: 12. Balance Sheet (Non-Consolidated)

    12. Balance Sheet(Non-Consolidated) (¥ million,%) (¥ million,%) FY 14/8 15/8 Change(the previous year) First-half 15/8 First-half 16/8 Change(the previous year) Result Composition Result Composition Result Change % Result Composition Result Composition Result Change % Current assets 26,568 74.1 26,4

Nagaileben — H1 FY2016 Earnings Presentation on 6ix